News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
These re-agent and diagnostic test kits come with 99.7% accuracy
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Subscribe To Our Newsletter & Stay Updated
